Efficacy and safety of enzalutamide, abiraterone and cabazitaxel in post-docetaxel treatment of castration-resistant prostate cancer: meta-analysis data

Background. Castration-resistant prostate cancer (CRPC) is wide-spread severe disease in many regions of the world. Enzalutamide, abiraterone and cabazitaxel have been recently registered for the treatment of this condition.Objective: to perform indirect comparison of enzalutamide, abiraterone and c...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: P. V. Mazin, N. K. Mazina
Formato: Artigo
Idioma:Russo
Publicado em: ABV-press 2017-12-01
Colecção:Onkourologiâ
Assuntos:
enzalutamide
abiraterone
cabazitaxel
castration-resistant prostate cancer
indirect comparisson
meta-analysis
overall survival
Acesso em linha:https://oncourology.abvpress.ru/oncur/article/view/772
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados